Last updated: February 14, 2026
What Is the Market Status of Drug NDC: 62559-0340?
The drug identified by NDC 62559-0340 is Vosevi (sofosbuvir, velpatasvir, and voxilaprevir). Approved by the FDA in 2017, Vosevi addresses hepatitis C virus (HCV) infections, specifically genotypes 1-6, in treatment-experienced and treatment-naive patients. The drug is marketed by Gilead Sciences.
Vosevi has secured a significant share in the HCV treatment sector as part of Gilead’s broader antiviral portfolio. The drug's efficacy, safety profile, and resistance management allow its widespread prescribing.
What Are the Sales and Market Penetration Trends?
Historical Sales Data:
- In 2020, Gilead reported Vosevi sales estimating approximately $0.3 billion globally.
- Sales declined slightly in 2021, attributable to market saturation, competition, and pricing pressures.
- Estimated global sales in 2022 ranged between $250-300 million.
Market Penetration:
- Vosevi's market share within HCV therapies remains relatively stable but faces headwinds from newer agents and generic competition in some regions.
- In the U.S., the drug accounts for roughly 10-15% of Gilead's HCV sales, with higher penetration among treatment-experienced populations.
Key Competitors:
- Mavyret (glecaprevir/pibrentasvir) by AbbVie
- Epclusa (sofosbuvir/velpatasvir) by Gilead
- Zepatier (elbasvir/grazoprevir) by Merck
These competitors influence pricing strategies and patient access.
What Are the Price Projections and Cost Dynamics?
Pricing in the U.S.:
- List Price: Approximately $74,760 for a 12-week course (the typical treatment duration).
- Average Net Price: After discounts and rebates, estimated at $25,000–$35,000 per course.
- Reimbursement Trends: Insurance providers tend to favor generics and more cost-effective regimens, pressuring prices downward.
Price Trends:
- Since approval, the list price has remained stable; however, net prices have decreased owing to negotiations and discounting.
- Pharmaco-economic pressures and the availability of generics in some regions push prices lower in emerging markets.
Future Price Dynamics:
- In mature markets, prices are unlikely to increase absent new indications or formulations.
- In regions with limited competition or high HCV prevalence, Gilead might retain higher prices.
- Introduction of biosimilar or generic versions could reduce prices by 30-50% within 3-5 years, following patent expirations in specific markets.
Regional Price Variations:
| Region |
List Price (USD) |
Typical Rebate/Discount |
Adjusted Selling Price |
| US |
$74,760 |
50-60% |
$25,000–$35,000 |
| EU |
$50,000–$60,000 |
30-50% |
$25,000–$35,000 |
| Emerging Markets |
$10,000–$20,000 |
40-60% |
$4,000–$8,000 |
(Data from IQVIA reports and pricing analysis services)
What Is the Outlook for Future Market and Price?
Market Size:
- Global HCV market estimated at $8–10 billion in 2022.
- Vosevi’s share remains limited but stable due to competition and treatment guidelines favoring shorter, cheaper regimens.
Growth Drivers:
- Increased HCV screening, especially in underserved regions.
- Expansion into pediatric and co-infection indications.
- Pricing pressures impacting revenue growth.
Risks:
- Patent expirations in key territories starting 2025.
- Emerging generics could erode market share and reduce prices.
- Competition from new direct-acting antivirals (DAAs) reported to have higher efficacy or shorter regimens.
Projection Summary:
- Near-term sales expected to remain between $200–$300 million annually in mature markets.
- Prices likely to decline 10–20% over the next five years, especially in markets with biosimilar competition.
- Long-term outlook depends on the evolution of HCV treatment paradigms, market saturation, and regulatory developments.
Key Takeaways
- NDC 62559-0340 (Vosevi) generated about $250–300 million globally in recent years.
- The drug maintains a niche among treatment-experienced patients with a stable but plateaued market share.
- Price per treatment course currently ranges from $25,000 to $35,000 after discounts.
- Market growth is constrained by competition, patent expiry, and emerging generics.
- Future revenue depends heavily on global HCV prevalence, screening programs, and regulatory pressures.
5 FAQs
Q1: Is Vosevi expected to lose significant market share in the next five years?
A1: Yes, especially as patent protections lapse and generics enter markets, leading to price reductions and increased competition.
Q2: How do pricing trends compare with other HCV therapies?
A2: Vosevi’s prices are comparable to Epclusa and Mavyret, with consistent discounts due to market saturation and policy pressures favoring cheaper alternatives.
Q3: Are there regional differences in Vosevi pricing?
A3: Yes, prices are notably lower in Europe and emerging markets due to negotiations, patent status, and healthcare system differences.
Q4: What factors could drive an increase in Vosevi’s market share?
A4: Expanded approved indications, improved clinician awareness, and increased testing could contribute to higher uptake.
Q5: Will new treatments impact Vosevi’s pricing?
A5: Likely. Advances that offer shorter, more effective, or less costly regimens typically reduce Vosevi’s market share and pricing power.
Sources:
- Gilead Sciences. Vosevi label approval, 2017.
- IQVIA. Global HCV market reports, 2022.
- FDA. Drug Approval Packages, 2017.
- Pricing data compiled from market access reports, 2022.
- Industry analyst projections and peer-reviewed market assessments.
